2/10
09:34 am
apre
Rating for APRE
Low
Report
Rating for APRE
2/10
09:34 am
apre
Rating for APRE
Low
Report
Rating for APRE
1/29
01:02 pm
apre
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.
Low
Report
Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.